<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.108241</article-id><article-id pub-id-type="publisher-id">ACM-37008</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20200800000_18571229.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  Mir-135a-3p在无功能垂体腺瘤中的表达及对其侵袭性的影响
  Expression of MiR-135a-3p in Non-Functional Pituitary Adenomas and Its Effect on Its Invasiveness
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>谭</surname><given-names>维康</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>成浩</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>建鹏</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>闫</surname><given-names>志勇</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青岛大学附属医院神经外科，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>05</day><month>08</month><year>2020</year></pub-date><volume>10</volume><issue>08</issue><fpage>1610</fpage><lpage>1616</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：本文探讨miR-135a-3p在无功能垂体腺瘤(NFPA)中的表达及其对NFPA细胞侵袭性的影响。方法：采用实时定量PCR分别检测50例的NFPA组织(侵袭性和非侵袭性各25例)；培育正常大鼠垂体瘤细胞株，随机分为实验组和阴性对照组，分别转染miR-135a-3p inhibitor和miR-135a-3p NC，采用实时荧光定量PCR检测miR-135a-3p的表达；转染后分别进行CCK8实验检测垂体瘤细胞增殖能力；Transwell实验检测垂体瘤细胞的迁移能力。结果：结果显示，侵袭性NFPA组中miR-135a-3p表达量明显高于非侵袭性NFPA组(P &lt; 0.05)；转染miR-135a-3p inhibitor后垂体瘤细胞株的细胞增殖能力较阴性对照组下降(P &lt; 0.05)；miR-135a-3p inhibitor组垂体瘤细胞与阴性对照组相比细胞迁移能力下降(P &lt; 0.05)。结论：miR-135a-3p在NFPA中过表达，其可能调控垂体瘤细胞的增殖从而促进其侵袭行为的发生。
    Objective: To investigate the expression of miR-135a-3p in nonfunctional pituitary adenoma (NFPA) and its effect on the invasion of NFPA cells. Methods: 50 NFPA tissues (25 invasive and 25 non-invasive) were detected by real-time quantitative PCR. Normal rat pituitary tumor cell lines were cultured and randomly divided into the experimental group and the negative control group. miR-135a-3p inhibitor and miR-135a-3P NC were transfected respectively, and the expression of miR-135a-3P was detected by quantitative real-time PCR. CCK8 assay was used to detect the proliferation of pituitary tumor cells after transfection. Transwell assay was used to detect the migration ability of pituitary tumor cells. Results: The expression level of miR-135a-3p in the invasive NFPA group was significantly higher than that in the non-invasive NFPA group (P &lt; 0.05). After transfection with miR-135a-3p inhibitor, the proliferation ability of pituitary tumor cell lines decreased compared with the negative control group (P &lt; 0.05). Cell migration was decreased in the miR-135a-3p inhibitor group compared with the negative control group (P &lt; 0.05). Conclusion: Overexpression of miR-135a-3p in NFPA may regulate the proliferation of pituitary tumor cells and promote their invasion. 
  
 
</p></abstract><kwd-group><kwd>miR-135a-3p，无功能垂体腺瘤，增殖，侵袭性, MiR-135a-3p</kwd><kwd> Non-Functional Pituitary Adenomas</kwd><kwd> Proliferation</kwd><kwd> Invasiveness</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>Mir-135a-3p在无功能垂体腺瘤中的表达及对其侵袭性的影响</title><p>谭维康<sup>*</sup>，王成浩，王建鹏，闫志勇<sup>*</sup></p><p>青岛大学附属医院神经外科，山东 青岛</p><disp-formula id="hanspub.37008-formula17"><graphic xlink:href="//html.hanspub.org/file/12-1571486x5_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2020年7月25日；录用日期：2020年8月6日；发布日期：2020年8月13日</p><disp-formula id="hanspub.37008-formula18"><graphic xlink:href="//html.hanspub.org/file/12-1571486x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：本文探讨miR-135a-3p在无功能垂体腺瘤(NFPA)中的表达及其对NFPA细胞侵袭性的影响。方法：采用实时定量PCR分别检测50例的NFPA组织(侵袭性和非侵袭性各25例)；培育正常大鼠垂体瘤细胞株，随机分为实验组和阴性对照组，分别转染miR-135a-3p inhibitor和miR-135a-3p NC，采用实时荧光定量PCR检测miR-135a-3p的表达；转染后分别进行CCK8实验检测垂体瘤细胞增殖能力；Transwell实验检测垂体瘤细胞的迁移能力。结果：结果显示，侵袭性NFPA组中miR-135a-3p表达量明显高于非侵袭性NFPA组(P &lt; 0.05)；转染miR-135a-3p inhibitor后垂体瘤细胞株的细胞增殖能力较阴性对照组下降(P &lt; 0.05)；miR-135a-3p inhibitor组垂体瘤细胞与阴性对照组相比细胞迁移能力下降(P &lt; 0.05)。结论：miR-135a-3p在NFPA中过表达，其可能调控垂体瘤细胞的增殖从而促进其侵袭行为的发生。</p><p>关键词 :miR-135a-3p，无功能垂体腺瘤，增殖，侵袭性</p><disp-formula id="hanspub.37008-formula19"><graphic xlink:href="//html.hanspub.org/file/12-1571486x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/12-1571486x8_hanspub.png" /> <img src="//html.hanspub.org/file/12-1571486x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>垂体腺瘤是常见的中枢神经系统肿瘤之一，占颅内肿瘤的10%~25%，垂体腺瘤在生物学功能上大致分为三种类型：良性腺瘤、侵袭性垂体腺瘤、垂体腺癌。按照内分泌功能分为：功能性垂体腺瘤和无功能性垂体腺瘤，流行病学研究显示，无功能性垂体腺瘤(non-functioning pituitary adenomas NFPAs)约占所有PA的一半 [<xref ref-type="bibr" rid="hanspub.37008-ref1">1</xref>]。多项研究指出，侵袭性NFPA手术全切困难且复发率高，NFPA侵袭性是影响手术效果的关键因素，并与患者预后高度相关 [<xref ref-type="bibr" rid="hanspub.37008-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.37008-ref3">3</xref>]。MicroRNA是短片段(19~25个核苷酸，miRNA)非编码RNA，在调节许多生物过程中起着关键作用，包括发育、分化、肿瘤的迁移侵袭等 [<xref ref-type="bibr" rid="hanspub.37008-ref4">4</xref>]。研究 [<xref ref-type="bibr" rid="hanspub.37008-ref5">5</xref>] 表明，肿瘤细胞与正常细胞相比表现出异常的miR-135a表达谱，提示miR-135-3p在肿瘤形成和进展中可能发挥重要作用。然而mir-135a-3p在垂体腺瘤中的表达尚未有研究报道。</p></sec><sec id="s4"><title>2. 材料与方法</title><sec id="s4_1"><title>2.1. 组织标本来源</title><p>收集2018年6月~2020年3月青岛大学附属医院神经外科行垂体瘤手术患者50例NFPA组织标本(侵袭性、非侵袭性各25例)，组织标本离体−80℃保存备用。</p><p>侵袭性NFPA选择标准：具备下述3种情况之一者：</p><p>1) MRI显示肿瘤侵入海绵窦(Knosp分类的3、4级；Hardy-Wilson分类的4级)；</p><p>2) 组织病理学证实有其它周围组织侵袭(硬膜、骨质等组织侵犯)；</p><p>3) 术中见海绵窦、硬膜及骨质侵袭。</p><p>关于本研究的目的与研究过程，所有患者均知情同意，且获得本单位伦理委员会通过。</p></sec><sec id="s4_2"><title>2.2. 细胞、特殊试剂来源</title><p>大鼠垂体瘤细胞系(MMQ、GH3)购于ATCC细胞库；CCK-8试剂盒(东仁化学)；Lipofectamine3000 (Thermo)；Transwell (Millipore)；反转录试剂盒(Takara)；荧光定量PCR试剂盒(Takara)。</p></sec><sec id="s4_3"><title>2.3. qPCR检测NFPA中miR-135a表达水平</title><p>将垂体瘤标本组织块放入研钵中，加入液氮研磨3次，按每50~100 mg组织加入1 ml Trizol，离心沉淀后提取得总RNA，以总RNA为模板，按逆转录试剂盒说明书操作逆转录得到cDNA。取cDNA，根据实时荧光量PCR试剂盒说明书配制PCR体系进行反应。</p></sec><sec id="s4_4"><title>2.4. 细胞培养、转染与分组</title><p>在超净台中将用干冰保存的大鼠垂体瘤细胞悬液转入DMEM + 10% FBS培养基中培养，细胞培养箱环境温度为37℃，二氧化碳浓度为5%。将细胞随机分为阴性对照组与实验组。使用Lipofectamine3000分别转染miR-135a-3p inhibitor 和miR-135a-3p NC。分别将转染后的细胞采用qPCR技术检测MMQ与GH3细胞中的miR-135a-3p表达(引物序列见表1)。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Primer sequenc</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Gene</th><th align="center" valign="middle" >Upstream primer</th><th align="center" valign="middle" >Downstream primer</th></tr></thead><tr><td align="center" valign="middle" >miR-135a-3p</td><td align="center" valign="middle" >5'-TGCGGTGTAGGGATGGAAGCCAT-3</td><td align="center" valign="middle" >5'-CCAGTGCAGGGTCCGAGGT -3'</td></tr><tr><td align="center" valign="middle" >GAPDH</td><td align="center" valign="middle" >5'-AAGAAGGTGGTGAAGCAGGC-3'</td><td align="center" valign="middle" >5'-TCCACCACCCTGTTGCTGTA-3'</td></tr><tr><td align="center" valign="middle" >U6</td><td align="center" valign="middle" >5'-CTCGCTTCGGCAGCACA -3'</td><td align="center" valign="middle" >5'-AACGCTTCACGAATTTGCGT -3'</td></tr></tbody></table></table-wrap><p>表1. 引物序列</p><p>(60℃退火30 s)。</p></sec><sec id="s4_5"><title>2.5. 细胞增殖活性检测(CCK8)</title><p>将各组细胞接种于3个96孔板内，各组设置三个复孔，各个时点(24 h、48 h、72 h)向每孔加入10 μL CCK-8 溶液，在37℃的培养箱中避光孵育2 h，应用酶标仪测定450 nm波长处各孔不同时点的光密度(OD)值。</p></sec><sec id="s4_6"><title>2.6. 细胞迁移活性检测(Transwell)</title><p>将各组细胞于转染12 h后，离心、去上清，以500 μL无血清培养基重悬细胞，对细胞进行计数；将各组细胞加入Transwell小室内，每室加入2 &#215; 105个细胞。小室置于24孔板中，含血清完全培养基中继续培养48 h，用移液枪加入到流式管中清洗后检测管内细胞数目。</p></sec><sec id="s4_7"><title>2.7. 统计学方法</title><p>应用SPSS22.0软件进行统计分析，计量资料以均数 &#177; 标准差( x &#175; &#177; s )表示，两组间比较和组内比较分别采用成组t检验和配对t检验；以P &lt; 0.05表示差异有统计学意义。</p></sec></sec><sec id="s5"><title>3. 结果</title><sec id="s5_1"><title>3.1. MiR-135a-3p在NFPA组织中的表达情况</title><p>本实验共收集侵袭性与非侵袭性NFPA标本各25例。在侵袭性NFPA组织中，miR-135a-3p相对表达量与非侵袭性NFPA相比，明显高表达，两者比较P &lt; 0.05 (见图1)。</p><p>图1. MiR-135a-3p在侵袭性与非侵袭性NFPA组织中的差异表达</p></sec><sec id="s5_2"><title>3.2. 细胞转染结果</title><p>转染后运用qPCR分别检测大鼠垂体瘤细胞株中的miR-135a-3p的表达，其中实验组miR-135a-3p表达量较NC组与空白组明显下降(P &lt; 0.05)，而NC组与空白组相比较未见明显差异(见图2)。</p><p>图2. 两组垂体瘤细胞转染miR-135a-3p-inhibitor后表达情况</p></sec><sec id="s5_3"><title>3.3. 细胞增殖实验结果</title><p>CCK-8法检测结果显示，与NC组与空白对照组比较，miR-135a-3p inhibitor组GH3与MMQ细胞的增殖活性明显降低，P &lt; 0.05 (图3)。上述结果表明敲降miR-135a-3p抑制了垂体瘤细胞增殖。</p><p>图3. 转染miR-135a-3p-inhibitor，垂体瘤细胞增殖活性明显减低</p></sec><sec id="s5_4"><title>3.4. 细胞迁移实验结果</title><p>Transwell实验检测结果显示，miR-135a-3p inhibitor组，与NC组和空白对照组比较，miR-135a-3p inhibitor组中垂体瘤细胞迁移跨胶能力显著下降(均P &lt; 0.05)。上述结果表明，敲降miR-135a-3p抑制了垂体瘤细胞的迁移及侵袭能力(图4)。</p><p>图4. 转染miR-135a-3p-inhibitor，垂体瘤细胞迁移能力下降</p></sec></sec><sec id="s6"><title>4. 讨论</title><p>垂体腺瘤起源于蝶鞍内脑垂体细胞，约占所有颅内肿瘤的10%~25%。垂体腺瘤按照临床表现和血清激素水平可分为功能性腺瘤和无功能性腺瘤，泌乳素瘤是最常见的功能性垂体腺瘤，多巴胺激动剂(DA)是主要的治疗方法 [<xref ref-type="bibr" rid="hanspub.37008-ref6">6</xref>]。而无功能垂体腺瘤尚未有明确疗效的药物，临床上仍以手术为主。先前的研究已经证实了大多数垂体瘤的良性性质。然而在临床上，约三分之一的垂体腺瘤呈浸润性生长。例如垂体腺瘤常表现出朝向外周组织、神经侵袭性生长，并因此被称为侵袭性垂体瘤 [<xref ref-type="bibr" rid="hanspub.37008-ref7">7</xref>]。侵袭性垂体腺瘤进展快速，在手术过程中是很难完全切除，并且手术后短期复发率高，是临床治疗的一大挑战。垂体瘤的侵袭性生长是引起疾病的复发，进一步影响临床疗效和预后的重要因素之一。因此，垂体腺瘤的侵袭性是影响手术效果的关键因素，并与患者预后高度相关 [<xref ref-type="bibr" rid="hanspub.37008-ref8">8</xref>]。</p><p>miRNA是一类由19~25个核苷酸组成的内源性非编码单链小分子RNA，通过与靶基因的配对，转录后调控基因的表达，在器官形成、细胞增殖凋亡、肿瘤形成等一系列生命过程中起着重要的调控作用 [<xref ref-type="bibr" rid="hanspub.37008-ref9">9</xref>]。近些年的研究表明，miR-135a-3p在多种恶性肿瘤的中异常表达。例如，在乳腺癌、鼻咽癌等肿瘤中低表达 [<xref ref-type="bibr" rid="hanspub.37008-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.37008-ref11">11</xref>]，但在肝癌、结肠癌等肿瘤中却异常高表达 [<xref ref-type="bibr" rid="hanspub.37008-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.37008-ref13">13</xref>]，下调肿瘤细胞中miR135a-3p水平可抑制肿瘤的生长及转移速度。由此可见，miR-135a-3p在不同的肿瘤中存在明显的差异性。</p><p>miR-135a-3p在垂体腺瘤中的作用机制尚未有研究报道，本文中我们对其在NFPA中的表达及对肿瘤侵袭性的影响进行了初步研究。首先我们应用实时定量PCR技术分别检测侵袭性与非侵袭性NFPA组织标本中miR-135a-3p的相对表达量，结果表明与非侵袭性NFPA对比，侵袭性NFPA中miR-135a-3p明显高表达。为了明确miR-135a-3p在垂体腺瘤中的作用机制，我们在细胞水平设计试验，将大鼠MMQ/GH3细胞株进行敲降转染，模拟低表达水平，转染成功后通过CCK8、Transwell实验表明低表达水平的miR-135a-3p抑制了肿瘤的增殖、迁移能力。</p></sec><sec id="s7"><title>5. 结论</title><p>综上所述，miR-135a-3p在侵袭性NFPA组织中过表达，敲降肿瘤细胞中miR-135a-3p水平，可以明显抑制垂体瘤细胞的增殖及迁移能力，提示miR-135a-3p在NFPA中可能通过影响肿瘤的增殖及迁移能力促进其侵袭性为的发生，为侵袭性NFPA的靶向治疗提供了新的方向。</p></sec><sec id="s8"><title>致谢</title><p>感谢闫志勇教授山东省自然科学基金项目(ZR2017MH077，EGFL7通过介导Notch信号通路调控GH垂体腺瘤侵袭生物学行为的机制研究)对于本研究的支持，感谢王建鹏主任对于文章撰写提供的指导，感谢王成浩同学提供的实验帮助。</p></sec><sec id="s9"><title>基金项目</title><p>山东省自然科学基金项目(ZR2017MH077)。</p></sec><sec id="s10"><title>文章引用</title><p>谭维康,王成浩,王建鹏,闫志勇. Mir-135a-3p在无功能垂体腺瘤中的表达及对其侵袭性的影响Expression of MiR-135a-3p in Non-Functional Pituitary Adenomas and Its Effect on Its Invasiveness[J]. 临床医学进展, 2020, 10(08): 1610-1616. https://doi.org/10.12677/ACM.2020.108241</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.37008-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Ezzat, S., Asa, S.L., Couldwell, W.T., et al. (2004) The	Prevalence of Pituitary Adenomas: A Systematic Review. Cancer, 101, 613-619. &lt;br&gt;https://doi.org/10.1002/cncr.20412</mixed-citation></ref><ref id="hanspub.37008-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Herbert, S.P. and Stainier, D.Y. (2011) Molecular Control of Endothelial Cell Behaviour during Blood Vessel Morphogenesis. Nature Reviews Molecular Cell Biology, 12, 551-564. &lt;br&gt;https://doi.org/10.1038/nrm3176</mixed-citation></ref><ref id="hanspub.37008-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Oldfield, E.H. (2014) Editorial: Management of Invasion by Pituitary Adenomas. Journal of Neurosurgery, 121, 501-503. &lt;br&gt;https://doi.org/10.3171/2014.5.JNS132817</mixed-citation></ref><ref id="hanspub.37008-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, Y., Hu, Y., fang, J.Y., et al. (2016) Gain-of-Function miRNA Signature by Mutant p53 Associates with Poor Cancer Outcome. Oncotarget, 7, 11056-11066.  
&lt;br&gt;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905457/ 
&lt;br&gt;https://doi.org/10.18632/oncotarget.7090</mixed-citation></ref><ref id="hanspub.37008-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Wang, Q.J., Zhang, H.C., Shen, X.J., et al. (2017) Serum microRNA-135a-5p as an Auxiliary Diagnostic Biomarker for Colorectal Cancer. Annals of Clinical Biochemistry, 54, 76-85. &lt;br&gt;https://doi.org/10.1177/0004563216638108</mixed-citation></ref><ref id="hanspub.37008-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Liu, X., Liu, Y., Gao, J., et al. (2018) Combination Treatment with Bromocriptine and Metformin in Patients with Bromocriptine-Resistant Prolactinomas: Pilot Study. World Neurosurgery, 115, 94-98.  
&lt;br&gt;https://doi.org/10.1016/j.wneu.2018.02.188</mixed-citation></ref><ref id="hanspub.37008-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Oldfield, E.H. (2014) Editorial: Management of Invasion by Pituitary Adenomas. Journal of Neurosurgery, 121, 501-503. &lt;br&gt;https://doi.org/10.3171/2014.5.JNS132817</mixed-citation></ref><ref id="hanspub.37008-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Ribatti, D., Nico, B. and Crivellato, E. (2009) Morphological and Molecular Aspects of Physiological Vascular Morphogenesis. Angiogenesis, 12, 101-111. &lt;br&gt;https://doi.org/10.1007/s10456-008-9125-1</mixed-citation></ref><ref id="hanspub.37008-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Sorel, O. and Dewals, B.G. (2016) MicroRNAs in Large Herpesvirus DNA Genomes: Recent Advances. BioMolecular Concepts, 7, 229-239. &lt;br&gt;https://doi.org/10.1515/bmc-2016-0017</mixed-citation></ref><ref id="hanspub.37008-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Ahmad, A., Zhang, W., Wu, M., et al. (2018) Tumor-Suppressive miRNA-135a Inhibits Breast Cancer Cell Proliferation by Targeting ELK1 and ELK3 Oncogenes. Genes Genomics, 40, 243-251.  
&lt;br&gt;https://doi.org/10.1007/s13258-017-0624-6</mixed-citation></ref><ref id="hanspub.37008-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Wang, L.X., Kang, Z.P., Yang, Z.C., et al. (2018) MicroRNA-135a Inhibits Nasopharyngeal Carcinoma Cell Proliferation through Targeting In-Terleukin-17. Cellular Physiology &amp; Biochemistry, 46, 2232-2238.  
&lt;br&gt;https://doi.org/10.1159/000489591</mixed-citation></ref><ref id="hanspub.37008-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Zeng, Y.B., Liang, X.H., Zhang, G.X., et al. (2016) miRNA-135a Promotesepatocellular Carcinoma Cell Migration and Invasion by Targeting Forkhead Box O1. Cancer Cell International, 16, 63.  
&lt;br&gt;https://doi.org/10.1186/s12935-016-0328-z</mixed-citation></ref><ref id="hanspub.37008-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Zhou, W., Li, X., Liu, F., et al. (2012) MiR-135a Promotes Growth and Invasion of Colorectal Cancer via Metastasis Suppressor 1 In Vitro. Acta Biochimica et Biophysica Sinica (Shanghai), 44, 838-846.  
&lt;br&gt;https://doi.org/10.1093/abbs/gms071</mixed-citation></ref></ref-list></back></article>